(Q61921523)

English

Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma

clinical trial

In more languages

edit

Statements

instance of

clinical trial

0 references

title

Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Subjects With Advanced Multiple Myeloma (English)

0 references

medical condition

multiple myeloma

0 references

country

United States of America

0 references

start time

December 2006

0 references

end time

August 2008

0 references

number of participants

35

0 references

clinical trial phase

phase I clinical trial

0 references

research site

University of Southern California

0 references

Northwestern University

0 references

Dana–Farber Cancer Institute

0 references

Wayne State University

0 references

Cleveland Clinic

0 references

Fred Hutchinson Cancer Research Center

0 references

research subject recruitment status

completed

0 references

minimum age

18 year

0 references

study type

interventional study

0 references

Identifiers

ClinicalTrials.gov ID

NCT00425347

0 references

(Q61921523)

Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)